Nanomerics today announced that the Canadian Intellectual Property Office will allow key patent application underpinning its enkephalin pain therapeutic (patent application number - CA2754140) to proceed to grant. This patent supports Nanomerics’ pain therapeutics, including NM0127 and provides further assurances to potential partners on patent protection in key markets. Nanomerics will continue to defend its assets with key patent applications and ongoing patent prosecution. This is a major component of its business strategy.
Latest News and Events
Nanomerics CEO Andreas Schatzlein presents at the SCI's event "From the Brain to the Bank: The Journey of Creating Value from Science" organised by SCI's Science and Enterprise Group on the 12th of September.
Nanomerics to attend Biopharm America (5th - 6th September 2018) in Boston
Patent applications EP07789150.5 and EP03748286.6 will be allowed to grant by the European Patent Office, thus further strengthening Nanomerics’ patent portfolio and its business activities in the European Union. These two patents directly underpin Nanomerics’ key drug delivery technology - Nanomerics’ MET.
Nanomerics has entered into an Engineering and Physical Sciences Research Council (EPSRC) funded academic collaboration with scientists from Exeter University, Cambridge University, University College London and The Science and Technology Facilities Council’s Central Laser Facility. The £5.7 million pound grant will generate new data on the diagnosis and treatment of solid tumours with gold nanoparticles.
The Guardian today gives some background on Nanomerics’ Developement of a replacement for conventional opiate painkillers reporting on our recent scientific publication on NM127: "Natural painkiller nasal spray could replace addictive opioids".
The US health authorities have recently announced a national emergency related to the use and abuse of opioids estimate by the CDC to cost the US alone $78.5 billion a year and leading to the death of 90 Americans a day . The addictive nature of our current gold standard pain killers for strong pain is central to this crisis and non-addictive alternative medication is urgently needed. Nanomerics NM127 directly addresses these needs.
Nanomerics' CEO Andreas Schatzlein is presenting new data on the use of the MET platform for the potential treatement of epilepsy at the Epitarget annual meeting in Warsaw (11-13 Oct). Epitarget (https://www.epitarget.eu) is a large European research consortium funded by the EU under the FP7 framework. Nanomerics has joined this consortium to support the CNS delivery of novel therapeutics developed by the consortium partners.